Cargando…

P385: COMPARISON OF CLINICAL OUTCOMES AND ADVERSE EVENTS IN OLDER ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH NATIVE VS PEGYLATED ASPARAGINASE

Detalles Bibliográficos
Autores principales:	Agustina Perusini, Maria, Gupta, Vikas, Bankar, Aniket, Sibai, Jad, Minden, Mark, Maze, Dawn, Davidson, Marta, Richard-Carpentier, Guillaume, M Chan, Steven, Schuh, Andre, Yee, Karen, Atenafu, Eshetu, Sibai, Hassan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428392/ http://dx.doi.org/10.1097/01.HS9.0000968448.07133.3e

Ejemplares similares

Safety of re‐challenging adults with acute lymphoblastic leukemia with PEG‐asparaginase‐induced severe hypertriglyceridemia when treated with a pediatric‐inspired regimen
por: Al Nabhani, Ibrahim, et al.
Publicado: (2022)

Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia
por: Avramis, Vassilios I, et al.
Publicado: (2006)

Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report
por: Sibai, Jad, et al.
Publicado: (2022)

PB1768: IS NATIVE E-COLI OR PEG-ASPERAGINASE FORMULATION A HIGHER RISK FOR VTE DEVELOPMENT IN PATIENTS WITH POST TREATMENT ACUTE LYMPHOBLASTIC LEUKEMIA? A META-ANALYSIS
por: Seki, J. T., et al.
Publicado: (2022)

Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen
por: Chen, Ruiqi, et al.
Publicado: (2020)

P1040: FACTORS ASSOCIATED WITH THROMBOSIS IN MYELOFIBROSIS
por: Bankar, Aniket, et al.
Publicado: (2023)

Measurable residual disease monitoring provides insufficient lead-time to prevent morphological relapse in the majority of patients with core-binding factor acute myeloid leukemia
por: Puckrin, Robert, et al.
Publicado: (2020)

Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase
por: Modi, Tapasvi, et al.
Publicado: (2021)

P1020: SCREENING FOR PORTAL HYPERTENSION IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Davidson, M., et al.
Publicado: (2022)

PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: a systematic review
por: Medawar, Camile Valle, et al.
Publicado: (2020)

Novel site-specific PEGylated L-asparaginase
por: Meneguetti, Giovanna Pastore, et al.
Publicado: (2019)

Osteolytic lesion in polycythemia vera: First report and review of literature
por: Cheung, Verna, et al.
Publicado: (2022)

Impact of mutations on pregnancy outcome in patients with myeloproliferative neoplasms
por: Maze, Dawn, et al.
Publicado: (2022)

Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type
por: Kim, Hyun Jee, et al.
Publicado: (2018)

Correction: Novel site-specific PEGylated L-asparaginase
por: Meneguetti, Giovanna Pastore, et al.
Publicado: (2019)

Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial
por: Patel, B, et al.
Publicado: (2017)

Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data
por: Würthwein, Gudrun, et al.
Publicado: (2021)

Pharmacogenetics of asparaginase in acute lymphoblastic leukemia
por: Abaji, Rachid, et al.
Publicado: (2019)

Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach
por: Siebel, Christian, et al.
Publicado: (2021)

Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
por: Maese, Luke, et al.
Publicado: (2022)

Association of frailty with clinical outcomes in myelofibrosis: a retrospective cohort study
por: Bankar, Aniket, et al.
Publicado: (2021)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
por: Zhao, Davidson, et al.
Publicado: (2022)

Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort
por: England, James T., et al.
Publicado: (2022)

A Pharmacokinetic Study of Native E.coli Asparaginase for Acute Lymphoblastic Leukemia Treated with ThaiPOG Protocol
por: Chaweephisal, Phumin, et al.
Publicado: (2021)

Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study
por: Rizzari, Carmelo, et al.
Publicado: (2019)

L-Asparaginase induced thrombosis in acute lymphoblastic leukemia
por: Kulkarni, Ketan P.
Publicado: (2012)

Asparaginase-associated toxicity in children with acute lymphoblastic leukemia
por: Hijiya, Nobuko, et al.
Publicado: (2016)

L-asparaginase in the treatment of patients with acute lymphoblastic leukemia
por: Egler, Rachel A., et al.
Publicado: (2016)

National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?
por: Lussana, Federico, et al.
Publicado: (2020)

Biallelic disruption of DDX41 activity is associated with distinct genomic and immunophenotypic hallmarks in acute leukemia
por: Tierens, Anne, et al.
Publicado: (2023)

TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation
por: Zhao, Davidson, et al.
Publicado: (2023)

Acute pancreatitis following L-asparaginase in acute lymphoblastic leukemia
por: M'harzi, Soulaimane, et al.
Publicado: (2022)

Our Experiences with Asparaginase Activity Measurements in Children with Lymphoblastic Diseases
por: Müller, Judit, et al.
Publicado: (2023)

Successful treatment with apixaban of sinus venous thrombosis due to pegylated asparaginase in a young adult with T cell acute lymphoblastic leukemia: case report and review of management
por: Talamo, Laura, et al.
Publicado: (2017)

Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia
por: Khalil, Alaeddin, et al.
Publicado: (2020)

Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli‐Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia
por: Vrooman, Lynda M., et al.
Publicado: (2015)

L-asparaginase-induced Parotitis in an Elderly Patient with Acute Lymphoblastic Leukemia
por: Saburi, Masuho, et al.
Publicado: (2020)

L-Asparaginase Toxicity in the Treatment of Children and Adolescents with Acute Lymphoblastic Leukemia
por: Schmidt, Madalina-Petronela, et al.
Publicado: (2021)

PB1739: ADVERSE EFFECTS OF ASPARAGINASE IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
por: Chenbah, Wafa, et al.
Publicado: (2023)

Efficacy and safety of PEG-asparaginase versus E. coli L-asparaginase in Chinese children with acute lymphoblastic leukemia: a meta-analysis
por: Dai, Zhan-Jing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_00bm81cf11oba24r9mse4o9fip